Current Report Filing (8-k)
16 November 2022 - 01:19PM
Edgar (US Regulatory)
false0001006837TRUE295 Madison Avenue12th
FloorNew
YorkNY212235-269000010068372022-11-162022-11-160001006837hchc:CommonStockParValue0001PerShareMember2022-11-162022-11-160001006837hchc:PreferredStockPurchaseRightsMember2022-11-162022-11-16
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
|
|
|
|
|
|
|
Date of Report (Date of Earliest Event Reported): |
November 16, 2022 |
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
|
|
|
Delaware |
001-35210 |
54-1708481 |
|
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
|
|
|
|
|
|
|
|
|
|
295 Madison Avenue, 12th Floor
|
|
|
|
New York, NY
|
|
10017
|
|
(Address of principal executive offices) |
|
(Zip Code) |
|
|
|
|
|
|
|
|
|
|
Registrant’s telephone number, including area code: |
|
(212) 235-2690
|
Former name or former address, if changed since last
report
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
|
|
|
|
|
|
|
☐ |
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425) |
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the
Act:
|
|
|
|
|
|
|
|
|
|
Title of each class |
Trading Symbol |
Name of each exchange on which registered |
|
Common Stock, par value $0.001 per share |
VATE |
New York Stock Exchange |
|
Preferred Stock Purchase Rights
|
N/A |
New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth
company as defined in as defined in Rule 405 of the Securities Act
of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
|
|
|
|
|
|
|
|
|
|
Emerging growth company |
☐ |
|
|
|
|
|
|
|
|
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. |
☐ |
Item 7.01. Regulation FD Disclosure
On November 16, 2022, MediBeacon, Inc., a portfolio company within
the Pansend Life Sciences segment of INNOVATE Corp. (NYSE: VATE),
issued a press release titled “MediBeacon Receives $10 Million in
Amended Agreements with Huadong Medicine to Accelerate Development
of Transdermal GFR Measurement System”. A copy of the press release
is attached as Exhibit 99.1 to this Current Report on Form
8-K.
Exhibit 99.1 shall not be deemed filed for purposes of Section 18
of the Exchange Act, nor shall it be deemed incorporated by
reference in any filing under the Securities Act, except as shall
be expressly set forth by specific reference in a
filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
|
|
|
|
|
|
|
Exhibit No. |
Description |
|
99.1 |
|
|
104 |
Cover Page Interactive Data File (the cover page XBRL tags are
embedded within the inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly
authorized.
Date: November 16, 2022
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
INNOVATE Corp.
(Registrant)
|
|
|
|
|
|
|
|
By: |
/s/ Michael J. Sena |
|
|
Name: Michael J. Sena |
|
|
Title: Chief Financial Officer |
HC2 (NYSE:HCHC)
Historical Stock Chart
Von Jan 2023 bis Feb 2023
HC2 (NYSE:HCHC)
Historical Stock Chart
Von Feb 2022 bis Feb 2023
